Finding new ways to treat advanced prostate cancer
Official title: Testing ATAD2 as a new therapeutic target for advanced prostate cancer
Funded at University of California Los Angeles · NIH-11127423 · Data updated 2026-11-12
This research looks for new treatments for advanced prostate cancer, especially forms that no longer respond to standard therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $548,333 |
| NIH project number | 5R01CA287669-02 |
| Project ID | NIH-11127423 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is focused on understanding and treating advanced prostate cancer, particularly castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC).
✕Less likely to help
Patients with early-stage prostate cancer that is responsive to standard hormone therapies may not directly benefit from this specific research at its current stage.
What this research studies
Prostate cancer is a serious health concern for men, and advanced forms of the disease, particularly those resistant to hormone therapy, are very difficult to treat. This often leads to a more aggressive type called neuroendocrine prostate cancer (NEPC), which currently has no cure. Our team has found a protein called ATAD2 that is more active in these aggressive cancers. We are exploring if blocking ATAD2 with new medicines can stop cancer growth and offer a new path for patients.
Why it matters
Potential benefit: If successful, this work could lead to new medications for advanced prostate cancer, especially for patients whose cancer has become resistant to current treatments.
How similar studies have gone: Preliminary studies have shown that ATAD2 inhibitors can dramatically suppress the growth of neuroendocrine prostate cancer cells and tumors in laboratory settings.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Stoyanova, Tanya I — University of California Los Angeles
- Study coordinator: Stoyanova, Tanya I
Related research
Other NIH-funded projects on the same topics.
-
Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer
A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.
-
Boosting a tumor-suppressing enzyme to fight advanced prostate cancer
A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.
-
Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer
A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.
-
Genomic clues to guide therapy in advanced prostate cancer
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
-
DACH1-based test to predict therapy response in advanced prostate cancer
A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.
-
Understanding how doctors choose treatments to improve advanced prostate cancer care
A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.